Raptor Pharmaceutical Corp. Announces US$7.5 Million Securities Offering

NOVATO, California, December 18 - Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP),
today announced that it has entered into definitive agreements with
institutional investors to purchase 3,747,558 units for gross proceeds of
approximately US$7.5 million, before placement agent fees and offering
expenses.

(Logo: www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO)

The offering is made pursuant to the Form S-3 shelf registration
statement that was filed by Raptor with the Securities and Exchange
Commission (the "SEC"). The offering is expected to close on or about
December 22, 2009, subject to the satisfaction of customary closing
conditions. Raptor intends to use the net proceeds from the offering for
general corporate purposes, including activities related to further clinical
development of DR Cysteamine and for other working capital and operational
purposes.

The securities sold in this offering consist of one share of common stock
and one warrant to purchase 0.5 of a share of common stock for a period of
five years and one warrant to purchase 0.5 of a share of common stock for a
period of 18 months. Both warrants have an exercise price of US$2.45 per
share of common stock and are exercisable starting with the date that is 180
days from the closing of the offering. The shares of common stock and
warrants are immediately separable and will be issued separately.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann
Financial Services Inc. (Amex: LTS), acted as the exclusive placement agent
for this offering. CK Cooper & Co. acted as a selected dealer in this
transaction.

The offering is being made pursuant to an effective shelf registration
statement filed with the Securities and Exchange Commission. Copies of the
final prospectus supplement and accompanying prospectus relating to the
offering may be obtained from the Securities and Exchange Commission's
website at www.sec.gov, or from Ladenburg Thalmann & Co. Inc., 520
Madison Avenue, 9th Floor, New York, New York 10022.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or jurisdiction.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq: RPTP) ("Raptor") is dedicated to
speeding the delivery of new treatment options to patients by working to
improve existing therapeutics through the application of highly specialized
drug targeting platforms and formulation expertise. Raptor focuses on
underserved patient populations where it can have the greatest potential
impact. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, non-alcoholic
steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase
("ALDH2") deficiency, and a non-opioid solution designed to potentially treat
chronic pain.

Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins that are designed to
target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events or our future results of operation or future
financial performance, including, but not limited to the following
statements: that Raptor will close the transaction by December 22, 2009; and
that any of Raptor's clinical and preclinical drug candidates will result in
approved therapeutics. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, which may cause the
Company's actual results to be materially different from these
forward-looking statements. Factors which may significantly change or prevent
the Company's forward looking statements from fruition include: that Raptor
may be unsuccessful at raising funds to continue its development programs;
Raptor may be unsuccessful in developing any products or acquiring products;
that Raptor's technology may not be validated as it progresses further and
its methods may not be accepted by the scientific community; that Raptor is
unable to retain or attract key employees whose knowledge is essential to the
development of its products; that unforeseen scientific difficulties develop
with the Company's process; that Raptor's patents are not sufficient to
protect essential aspects of its technology; that competitors may invent
better technology; and that Raptor's products may not work as well as hoped
or worse, that the Company's products may harm recipients. As well, Raptor's
products may never develop into useful products and even if they do, they may
not be approved for sale to the public. Raptor cautions readers not to place
undue reliance on any such forward-looking statements, which speak only as of
the date they were made. Certain of these risks, uncertainties, and other
factors are described in greater detail in the Company's filings from time to
time with the Securities and Exchange Commission (the "SEC"), which Raptor
strongly urges you to read and consider, including Raptor's current report on
Form 8-K as filed with the SEC on November 17, 2009; the joint proxy
statement/prospectus on Form S-4 filed with the SEC on August 19, 2009;
Raptor's annual report on Form 10-K filed with the SEC on March 27, 2009; and
Raptor's quarterly report on Form 10-Q filed with the SEC on August 11, 2009,
all of which are available free of charge on the SEC's web site at
www.sec.gov. Subsequent written and oral forward-looking statements
attributable to Raptor or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth in
Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or
obligation to update any forward-looking statements.

    For more information, please contact:

    Kim R. Tsuchimoto, CFO
    +1-415-382-1390
    ktsuchimoto@raptorpharma.com

    The Ruth Group

    Sara Ephraim Pellegrino (investors)
    +1-646-536-7002
    spellegrino@theruthgroup.com

    Janine McCargo (media)
    +1-646-536-7033
    jmccargo@theruthgroup.com

Kim R. Tsuchimoto, CFO, +1-415-382-1390, ktsuchimoto at raptorpharma.com; or The Ruth Group, Sara Ephraim Pellegrino (investors), +1-646-536-7002, spellegrino at theruthgroup.com; or Janine McCargo (media), +1-646-536-7033, jmccargo at theruthgroup.com